Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development

Dongxi Xiang; Aina He; Rong Zhou; Yonggang Wang; Xiuying Xiao; Ting Gong; Wenyan Kang; Xiaolin Lin; Xiaochen Wang; PDO-based DST Consortium; Lianxin Liu; Ye-Guang Chen; Shaorong Gao; Yingbin Liu

doi:10.7150/thno.96027

Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development

Theranostics. 2024 May 27;14(8):3300-3316. doi: 10.7150/thno.96027. eCollection 2024.

Authors

Dongxi Xiang^{1

2}, Aina He³, Rong Zhou^{4

5}, Yonggang Wang³, Xiuying Xiao⁶, Ting Gong⁷, Wenyan Kang^{8

9}, Xiaolin Lin⁶, Xiaochen Wang¹⁰; PDO-based DST Consortium; Lianxin Liu^{11

12}, Ye-Guang Chen^{13

14}, Shaorong Gao^{15

16

17}, Yingbin Liu^{1

2}

Affiliations

¹ State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200232, PRC.
² Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200127, PRC.
³ Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233 PRC.
⁴ Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200125, PRC.
⁵ National Center of Stomatology, National Clinical Research Center for Oral Disease, Shanghai 200011, PRC.
⁶ Department of Oncology, Ren Ji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, PRC.
⁷ Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, PRC.
⁸ Department of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, PRC.
⁹ Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Boao Research Hospital), Hainan 571434, PRC.
¹⁰ Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88, Jiefang Road, Hangzhou, Zhejiang 310009, PRC.
¹¹ Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui 230001, PRC.
¹² Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui 230001, PRC.
¹³ The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100190, PRC.
¹⁴ The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330047, China.
¹⁵ Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200120, PRC.
¹⁶ Frontier Science Center for Stem Cell Research, Tongji University, 1239 Siping Road, Shanghai 200092, PRC.
¹⁷ Shanghai Key Laboratory of Maternal-Fetal Medicine, Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, PRC.

Abstract

Patient-derived organoids (PDOs) have emerged as a promising platform for clinical and translational studies. A strong correlation exists between clinical outcomes and the use of PDOs to predict the efficacy of chemotherapy and/or radiotherapy. To standardize interpretation and enhance scientific communication in the field of cancer precision medicine, we revisit the concept of PDO-based drug sensitivity testing (DST). We present an expert consensus-driven approach for medication selection aimed at predicting patient responses. To further standardize PDO-based DST, we propose guidelines for clarification and characterization. Additionally, we identify several major challenges in clinical prediction when utilizing PDOs.

Keywords: Drug sensitivity testing (DST); Expert consensus; Organoid; Patient-derived organoids (PDOs); Precision medicine.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Consensus*
Drug Development* / methods
Drug Screening Assays, Antitumor / methods
Humans
Neoplasms* / drug therapy
Organoids* / drug effects
Precision Medicine* / methods

Substances

Antineoplastic Agents